Cargando…

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

BACKGROUND AND AIMS: There is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine against SARS-CoV-2 among Indians. METHODS: We conducted a 6-month longitudinal study in vaccinated healthcare workers by ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Awadhesh Kumar, Phatak, Sanjeev Ratnakar, Singh, Ritu, Bhattacharjee, Kingshuk, Singh, Nagendra Kumar, Gupta, Arvind, Sharma, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Diabetes India. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816907/
https://www.ncbi.nlm.nih.gov/pubmed/35150961
http://dx.doi.org/10.1016/j.dsx.2022.102424
_version_ 1784645525688025088
author Singh, Awadhesh Kumar
Phatak, Sanjeev Ratnakar
Singh, Ritu
Bhattacharjee, Kingshuk
Singh, Nagendra Kumar
Gupta, Arvind
Sharma, Arvind
author_facet Singh, Awadhesh Kumar
Phatak, Sanjeev Ratnakar
Singh, Ritu
Bhattacharjee, Kingshuk
Singh, Nagendra Kumar
Gupta, Arvind
Sharma, Arvind
author_sort Singh, Awadhesh Kumar
collection PubMed
description BACKGROUND AND AIMS: There is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine against SARS-CoV-2 among Indians. METHODS: We conducted a 6-month longitudinal study in vaccinated healthcare workers by serially measuring quantitative anti-spike antibody at 3-weeks, 3-months and 6-months after the completion of second dose. Geometric mean titer (GMT) and linear mixed models were used to assess the dynamics of antibody levels at 6 months. RESULTS: Of the 481 participants, GMT of anti-spike antibody decreased by 56% at 6-months regardless of age, gender, blood group, body-mass index and comorbidities in 360 SARS-CoV-2 naive individuals but significantly more in hypertensives. Participants with past infection had significantly higher GMT at all time points compared to the naive individuals. Among SARS-CoV-2 naive cohorts, a significantly higher GMT was noted amongst the Covishield recipients at all time points, but there was a 44% decline in GMT at 6-month compared to the peak titer period. Decline in GMT was insignificant (8%) in Covaxin recipients at 6-month despite a lower GMT at all time points vs. Covishield. There was 5.6-fold decrease in seropositivity rate at 6-month with both vaccines. Participants with type 2 diabetes mellitus have a lower seropositivity rate at all the time points. Seropositivity rate was significantly higher with Covishield vs. Covaxin at all time points except at 6-month where Covaxin recipients had a higher seropositivity rate but no difference noted in propensity-matched analysis. CONCLUSIONS: There is waning humoral antibody response following two doses of either vaccine at six months. Covishield recipients had a higher anti-spike antibody GMT compared with Covaxin at all-time points, however a significant decline in antibody titers was seen with Covishield but not with Covaxin at 6-months.
format Online
Article
Text
id pubmed-8816907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Diabetes India. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88169072022-02-07 Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study Singh, Awadhesh Kumar Phatak, Sanjeev Ratnakar Singh, Ritu Bhattacharjee, Kingshuk Singh, Nagendra Kumar Gupta, Arvind Sharma, Arvind Diabetes Metab Syndr Covid19 and Vaccines BACKGROUND AND AIMS: There is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine against SARS-CoV-2 among Indians. METHODS: We conducted a 6-month longitudinal study in vaccinated healthcare workers by serially measuring quantitative anti-spike antibody at 3-weeks, 3-months and 6-months after the completion of second dose. Geometric mean titer (GMT) and linear mixed models were used to assess the dynamics of antibody levels at 6 months. RESULTS: Of the 481 participants, GMT of anti-spike antibody decreased by 56% at 6-months regardless of age, gender, blood group, body-mass index and comorbidities in 360 SARS-CoV-2 naive individuals but significantly more in hypertensives. Participants with past infection had significantly higher GMT at all time points compared to the naive individuals. Among SARS-CoV-2 naive cohorts, a significantly higher GMT was noted amongst the Covishield recipients at all time points, but there was a 44% decline in GMT at 6-month compared to the peak titer period. Decline in GMT was insignificant (8%) in Covaxin recipients at 6-month despite a lower GMT at all time points vs. Covishield. There was 5.6-fold decrease in seropositivity rate at 6-month with both vaccines. Participants with type 2 diabetes mellitus have a lower seropositivity rate at all the time points. Seropositivity rate was significantly higher with Covishield vs. Covaxin at all time points except at 6-month where Covaxin recipients had a higher seropositivity rate but no difference noted in propensity-matched analysis. CONCLUSIONS: There is waning humoral antibody response following two doses of either vaccine at six months. Covishield recipients had a higher anti-spike antibody GMT compared with Covaxin at all-time points, however a significant decline in antibody titers was seen with Covishield but not with Covaxin at 6-months. Diabetes India. Published by Elsevier Ltd. 2022-02 2022-02-05 /pmc/articles/PMC8816907/ /pubmed/35150961 http://dx.doi.org/10.1016/j.dsx.2022.102424 Text en © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Covid19 and Vaccines
Singh, Awadhesh Kumar
Phatak, Sanjeev Ratnakar
Singh, Ritu
Bhattacharjee, Kingshuk
Singh, Nagendra Kumar
Gupta, Arvind
Sharma, Arvind
Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title_full Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title_fullStr Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title_full_unstemmed Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title_short Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
title_sort humoral antibody kinetics with chadox1-ncov (covishield™) and bbv-152 (covaxin™) vaccine among indian healthcare workers: a 6-month longitudinal cross-sectional coronavirus vaccine-induced antibody titre (covat) study
topic Covid19 and Vaccines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816907/
https://www.ncbi.nlm.nih.gov/pubmed/35150961
http://dx.doi.org/10.1016/j.dsx.2022.102424
work_keys_str_mv AT singhawadheshkumar humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT phataksanjeevratnakar humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT singhritu humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT bhattacharjeekingshuk humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT singhnagendrakumar humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT guptaarvind humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy
AT sharmaarvind humoralantibodykineticswithchadox1ncovcovishieldandbbv152covaxinvaccineamongindianhealthcareworkersa6monthlongitudinalcrosssectionalcoronavirusvaccineinducedantibodytitrecovatstudy